Exploration of Tumor-Intrinsic NLRP3 Signaling Regulators
肿瘤内在NLRP3信号调节因子的探索
基本信息
- 批准号:10309148
- 负责人:
- 金额:$ 6.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAutomobile DrivingBedsBindingBinding ProteinsCD8-Positive T-LymphocytesCancer PatientCellsClinicalClinical ResearchClustered Regularly Interspaced Short Palindromic RepeatsDNA Sequence AlterationDataDendritic CellsDevelopmentGenesGeneticGenetic MarkersHarvestHeat-Shock Proteins 70IL8RB geneImmuneImmune checkpoint inhibitorImmune systemImmunotherapyIn VitroInferiorInflammasomeInnate Immune SystemKnock-inLinkMalignant NeoplasmsMediatingModelingMutationMyeloid-derived suppressor cellsOncologyPD-1 blockadePathway interactionsPatient SelectionPatientsPharmacologyPlasmaPlayPopulationPre-Clinical ModelRegimenRegulationResistanceResistance developmentRoleSeriesSignal PathwaySignal TransductionSpecimenT-Cell ActivationTissue HarvestingTumor TissueUp-RegulationWorkanti-PD-1anti-PD-L1anti-PD1 antibodiesanti-PD1 therapyantibody immunotherapycancer typecheckpoint therapychemokinegain of function mutationgranulocyteimprovedin silicoin vivoinhibitor/antagonistmacrophagemelanomanovelprogrammed cell death ligand 1recruitresistance mechanismresponsetreatment strategytumor
项目摘要
Abstract. Despite the positive impact that checkpoint inhibitor immunotherapy has had on the field of oncology,
the majority of our cancer patients do not respond to this treatment strategy. It is now generally believed that a
more complete understanding of the mechanisms driving resistance to checkpoint inhibitor immunotherapy will
lead to the development of more effective immunotherapy regimens and to improved patient selection for specific
therapies. However, our understanding of active tumor-mediated resistance mechanisms that are more
responsive to pharmacologic targeting remains poor. Myeloid-derived suppressor cells (MDSCs) are an
immunosuppressive cell population that have been correlated with inferior responses to checkpoint inhibitor
therapy. Using pre-clinical models of different tumor types as well as clinical specimens harvested from
melanoma patients, we have determined that resistance to anti-PD-1 antibody (ab) immunotherapy is associated
with the recruitment of granulocytic MDSCs (PMN-MDSCs) into the tumor bed. Our subsequent studies have
shown that this accumulation of PMN-MDSCs in tumors is dependent upon the upregulation of CXCR2-
dependent chemokines via a Wnt5a-YAP1 signaling axis and that this pathway is, in turn, triggered by the release
of heat shock protein-70 (HSP70) by tumors in response to anti-PD-(L)1 antibody-mediated CD8+ T cell
activation. We have also determined that effector CD8+ T cells activate this signaling cascade by stimulating a
tumor intrinsic PD-L1-NLRP3 inflammasome pathway which facilitates the release of soluble HSP70. Our studies
further indicate that plasma levels of HSP70 are more significantly elevated in those patients who fail to respond
to anti-PD-1 antibody immunotherapy. Our cumulative data indicate that either alterations in the expression or
function of various regulators of the NLRP3 inflammasome may dictate the activation threshold of this resistance
pathway and therefore determine whether certain tumors respond or fail to respond to anti-PD-(L)1 checkpoint
inhibitor immunotherapies. While activation and regulation of the NLRP3 inflammasome has been well
characterized in various innate immune cell populations such as macrophages and dendritic cells, much less is
understood regarding the regulation of this signaling pathway in tumors. We have recently found that unique
NLRP3 binding partners exist in tumor tissues relative to innate immune cell populations. In silico studies also
show that mutations in the NLRP3 gene and various inflammasome regulators have been identified in various
cancer types, including melanoma. We therefore hypothesize that the identification of tumor-specific NLRP3-
binding proteins which regulate the activation state of this NLRP3 inflammasome-dependent signaling pathway
would provide putative novel pharmacologic targets capable of reversing this immunotherapy resistance
mechanism without impacting the innate immune system of the host. We further propose that genetic mutations
involving regulators of the NLRP3 inflammasome will explain certain forms of tumor resistance to anti-PD-(L)1
checkpoint inhibitor immunotherapy.
抽象的。尽管检查点抑制剂免疫疗法对肿瘤学领域产生了积极影响,
本港大部分癌症病人对这项治疗策略均无反应。现在人们普遍认为,
更全面地了解对检查点抑制剂免疫疗法产生耐药性的机制,
导致更有效的免疫治疗方案的开发,并改善患者的选择,
治疗然而,我们对活跃的肿瘤介导的耐药机制的理解,
对药理靶向的反应仍然很差。骨髓来源的抑制细胞(MDSC)是一种
免疫抑制细胞群与对检查点抑制剂反应较差相关
疗法使用不同肿瘤类型的临床前模型以及从
黑色素瘤患者,我们已经确定抗PD-1抗体(ab)免疫治疗的耐药性与黑色素瘤患者
随着粒细胞MDSC(PMN-MDSC)募集到肿瘤床中。我们随后的研究
表明PMN-MDSC在肿瘤中的这种积累依赖于CXCR 2 - 1的上调。
通过Wnt 5a-YAP 1信号轴的依赖性趋化因子,而这一途径反过来又被释放
抗PD-(L)1抗体介导的CD 8 + T细胞介导的肿瘤热休克蛋白70(HSP 70)的表达
activation.我们还确定了效应CD 8 + T细胞通过刺激细胞因子激活这种信号级联反应。
肿瘤内源性PD-L1-NLRP 3炎性体通路,其促进可溶性HSP 70的释放。我们的研究
这进一步表明,在那些没有应答的患者中,
抗PD-1抗体免疫疗法。我们的累积数据表明,无论是表达的改变,
NLRP 3炎性体的各种调节剂的功能可能决定这种抗性的激活阈值
因此确定某些肿瘤是否响应或未能响应抗PD-(L)1检查点
抑制剂免疫疗法。虽然NLRP 3炎性体的激活和调节已经被很好地研究,
其特征在于各种先天性免疫细胞群,如巨噬细胞和树突细胞,更不用说是
了解肿瘤中这种信号通路的调节。我们最近发现这种独特的
相对于先天免疫细胞群体,NLRP 3结合配偶体存在于肿瘤组织中。计算机模拟研究还
显示NLRP 3基因和各种炎性体调节因子的突变已经在各种肿瘤中被鉴定,
癌症类型,包括黑色素瘤。因此,我们假设,肿瘤特异性NLRP 3-
调节NLRP 3炎性体依赖性信号通路激活状态的结合蛋白
将提供能够逆转这种免疫疗法抗性的推定的新药理学靶点
这是一种不影响宿主先天免疫系统的机制。我们进一步提出基因突变
涉及NLRP 3炎性体的调节剂将解释某些形式的肿瘤对抗PD-(L)1的抗性
检查点抑制剂免疫疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brent Allen Hanks其他文献
Brent Allen Hanks的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brent Allen Hanks', 18)}}的其他基金
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
肿瘤NLRP3炎性体在抗PD-1抗体免疫治疗相关毒性产生中的作用
- 批准号:
10263391 - 财政年份:2021
- 资助金额:
$ 6.09万 - 项目类别:
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
肿瘤NLRP3炎性体在抗PD-1抗体免疫治疗相关毒性产生中的作用
- 批准号:
10454406 - 财政年份:2021
- 资助金额:
$ 6.09万 - 项目类别:
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
肿瘤NLRP3炎性体在抗PD-1抗体免疫治疗相关毒性产生中的作用
- 批准号:
10679040 - 财政年份:2021
- 资助金额:
$ 6.09万 - 项目类别:
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
研究 PD-L1:NLRP3 信号轴作为肿瘤对抗 PD-1 抗体免疫治疗适应性耐药的内在机制
- 批准号:
10670285 - 财政年份:2020
- 资助金额:
$ 6.09万 - 项目类别:
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
研究 PD-L1:NLRP3 信号轴作为肿瘤对抗 PD-1 抗体免疫治疗适应性耐药的内在机制
- 批准号:
10524203 - 财政年份:2020
- 资助金额:
$ 6.09万 - 项目类别:
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
研究 PD-L1:NLRP3 信号轴作为肿瘤对抗 PD-1 抗体免疫治疗适应性耐药的内在机制
- 批准号:
10459344 - 财政年份:2020
- 资助金额:
$ 6.09万 - 项目类别:
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
研究 PD-L1:NLRP3 信号轴作为肿瘤对抗 PD-1 抗体免疫治疗适应性抵抗的内在机制
- 批准号:
10159222 - 财政年份:2020
- 资助金额:
$ 6.09万 - 项目类别:
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
研究 PD-L1:NLRP3 信号轴作为肿瘤对抗 PD-1 抗体免疫治疗适应性抵抗的内在机制
- 批准号:
10388444 - 财政年份:2020
- 资助金额:
$ 6.09万 - 项目类别:
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion
黑色素瘤介导的树突状细胞耐受和免疫逃避
- 批准号:
9310397 - 财政年份:2015
- 资助金额:
$ 6.09万 - 项目类别:
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion
黑色素瘤介导的树突状细胞耐受和免疫逃避
- 批准号:
8967743 - 财政年份:2015
- 资助金额:
$ 6.09万 - 项目类别:
相似海外基金
Establishment of a method for evaluating automobile driving ability focusing on frontal lobe functions and its application to accident prediction
以额叶功能为中心的汽车驾驶能力评价方法的建立及其在事故预测中的应用
- 批准号:
20K07947 - 财政年份:2020
- 资助金额:
$ 6.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of the Effectiveness of Multi-Professional Collaborative Assessment of Cognitive Function and Automobile Driving Skills and Comprehensive Support
认知功能与汽车驾驶技能多专业协同评估效果评价及综合支持
- 批准号:
17K19824 - 财政年份:2017
- 资助金额:
$ 6.09万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of Flexible Automobile Driving Interface for Disabled People
残疾人灵活汽车驾驶界面开发
- 批准号:
25330237 - 财政年份:2013
- 资助金额:
$ 6.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Automobile driving among older people with dementia: the effect of an intervention using a support manual for family caregivers
患有痴呆症的老年人的汽车驾驶:使用家庭护理人员支持手册进行干预的效果
- 批准号:
23591741 - 财政年份:2011
- 资助金额:
$ 6.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)